Pre-Diligenced Cross-Border Bio Deal Flow.
Access curated seed & pre-seed healthtech ventures with Delaware flip structures, CDSCO clinical validation, and pre-negotiated co-investment terms.
Accredited Syndicate Deal Room
IGVP Bio Fund · Q3 Pipeline
NeuroPulse Diagnostics
AI-based EEG diagnostic platform. Indian clinical trial completed (60% savings).
CardioSensing Therapeutics
OncoTarget Bio
Full Data Room Access
Cap table, clinical protocols, & memo audit included
Why Institutional Investors Choose IGVP
Access pre-diligenced cross-border deal flow with structured terms and validated trial metrics
Traditional Market Friction
Fragmented Cross-Border Sourcing & Costly Solo Diligence
You want exposure to Global-US cross-border biotech deal flow, but sourcing is fragmented, diligence is expensive to run solo, and most emerging market deal flow arrives late and unvetted.
Common Obstacles & Bottlenecks:
High Diligence Cost
Spending $20k+ on legal and FDA pre-sub reviews for unvalidated seed deals.
Messy Cap Table Risk
Non-standard local company structures that fail Western VC investment committees.
Late Sourcing Entry
Receiving deal access only after primary seed allocation is exhausted.
Structured Operating System
Shortlisted, Memo-Backed Ventures with Pre-Structured Terms
IGVP Accelerator and Syndicate run structured sourcing and diligence upstream — you get access to shortlisted, memo-backed ventures with syndicate co-investment terms already pre-structured.
IGVP System Advantages:
Delaware C-Corp Standard
100% clean cap tables flipped into US Delaware holding structures.
Pre-Diligenced Memos
Comprehensive investment memos built by IGVP Venture Partners & Clinicians.
Guaranteed Syndicate Allocation
First-look co-investment rights on every Accelerator cohort graduate.
Syndicate Benefits
What You Get as an Institutional Investor
Syndicate Co-Investment
Syndicate co-investment rights alongside vetted Accelerator ventures, with memos pre-built by trained analysts.
First-Look Sprint Access
First-look access to the top 3 ventures fast-tracked out of each 72-Hour Bio-Design Sprint.
Direct Pipeline Visibility
Direct pipeline visibility into India-based biotech/medtech deal flow alongside US chapters.
Founder Speed Dating Mixers
Invitations to Founder & Investor Mixers for direct founder access ahead of formal rounds.
Role-Gated Discord & WhatsApp Communities
Self-segment upon entry into verified channels designed to accelerate co-founder matching, clinical trials, due diligence, and capital deployment.
Accredited Investor Check
Verified for accredited angel LPs, family offices & VC partners
💼 Institutional Investors Category
Category Channels
Cross-Pollination Engine: Members collide across co-founder matching and deal-flow channels to fuel the Tri-Engine Flywheel.
We have opened the $500K syndicate allocation for NeuroPulse Diagnostics. Delaware flip completed, CDSCO trial verified at 60% savings. Data room is live in #accredited-dealroom.
Reviewed the memo — clinical trial cost efficiency is outstanding. Reserving a $50K allocation for our family office.
Deploying Capital into Pre-Diligenced Healthtech
See how institutional VCs, family offices, and LP partners source top-tier founders and deploy capital via IGVP.
"The platform is our single source of truth for LP deal-room communications. It transformed how we source, diligence, and deploy Fund II capital."
David Chen
Managing Director · Nexus Capital
FUND II CLOSED
"IGVP deal flow comes pre-backed with clinical PIs and FDA regulatory roadmaps. We co-invested in 4 Series A healthtech rounds this year."
Victoria Sterling
General Partner · BioHealth VC
4 CO-INVESTMENTS
"Reserving syndicate allocations through IGVP gave our family office direct access to Series A healthtech deals previously locked in Tier-1 VCs."
Richard Cross
Chief Investment Officer · Cross Family Office
$5M CAPITAL ALLOCATED
"Demo Day on IGVP connects us directly with pre-screened bio-design founders. Our due diligence timeline was slashed by 60%."
Sophia Martinez
Partner · Frontier Health Fund
60% FASTER DILIGENCE
"The platform is our single source of truth for LP deal-room communications. It transformed how we source, diligence, and deploy Fund II capital."
David Chen
Managing Director · Nexus Capital
FUND II CLOSED
"IGVP deal flow comes pre-backed with clinical PIs and FDA regulatory roadmaps. We co-invested in 4 Series A healthtech rounds this year."
Victoria Sterling
General Partner · BioHealth VC
4 CO-INVESTMENTS
"Reserving syndicate allocations through IGVP gave our family office direct access to Series A healthtech deals previously locked in Tier-1 VCs."
Richard Cross
Chief Investment Officer · Cross Family Office
$5M CAPITAL ALLOCATED
"Demo Day on IGVP connects us directly with pre-screened bio-design founders. Our due diligence timeline was slashed by 60%."
Sophia Martinez
Partner · Frontier Health Fund
60% FASTER DILIGENCE